| pubmed-article:15466213 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15466213 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:15466213 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:15466213 | lifeskim:mentions | umls-concept:C0021745 | lld:lifeskim |
| pubmed-article:15466213 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:15466213 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:15466213 | lifeskim:mentions | umls-concept:C0599739 | lld:lifeskim |
| pubmed-article:15466213 | lifeskim:mentions | umls-concept:C1143119 | lld:lifeskim |
| pubmed-article:15466213 | pubmed:issue | 19 | lld:pubmed |
| pubmed-article:15466213 | pubmed:dateCreated | 2004-10-6 | lld:pubmed |
| pubmed-article:15466213 | pubmed:abstractText | NGR-TNF is a derivative of TNF-alpha, consisting of TNF fused to CNGRCG, a tumor vasculature-targeting peptide. Previous studies showed that NGR-TNF can exert synergistic antitumor effects with doxorubicin and with other chemotherapeutic drugs in murine models. In this study, we have investigated the role of endogenous IFN-gamma on the antitumor activity of NGR-TNF in combination with doxorubicin. The study was carried out using murine B16F1 melanoma and TS/A mammary adenocarcinoma implanted subcutaneously in (a) immunocompetent mice, (b) athymic nude mice, and (c) IFN-gamma-knockout mice. Synergism between NGR-TNF and doxorubicin was observed in immunocompetent mice but not in nude or IFN-gamma-knockout mice. Preadministration of a neutralizing anti-IFN-gamma antibody to immunocompetent mice inhibited the NGR-TNF/doxorubicin synergism, whereas administration of IFN-gamma to nude and to IFN-gamma-knockout mice restored the synergistic activity. The synergism in nude mice was restored also by transfecting tumor cells with the IFN-gamma cDNA. Administration of NGR-TNF in combination with IFN-gamma to nude mice, but not of NGR-TNF alone, doubled the penetration of doxorubicin in TS/A tumors. These findings point to a crucial role for locally produced IFN-gamma in tumor vascular targeting with NGR-TNF and doxorubicin. Finally, addition of IFN-gamma to the treatment of immunocompetent mice with NGR-TNF/doxorubicin induced only modest improvement in response, suggesting that exogenous IFN-gamma can improve the therapeutic activity of these drugs only in case of suboptimal production of endogenous IFN-gamma. | lld:pubmed |
| pubmed-article:15466213 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15466213 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15466213 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15466213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15466213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15466213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15466213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15466213 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15466213 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15466213 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:15466213 | pubmed:author | pubmed-author:CurnisFlavioF | lld:pubmed |
| pubmed-article:15466213 | pubmed:author | pubmed-author:SacchiAngelin... | lld:pubmed |
| pubmed-article:15466213 | pubmed:author | pubmed-author:CortiAngeloA | lld:pubmed |
| pubmed-article:15466213 | pubmed:author | pubmed-author:BelloneMatteo... | lld:pubmed |
| pubmed-article:15466213 | pubmed:author | pubmed-author:GasparriAnnaA | lld:pubmed |
| pubmed-article:15466213 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15466213 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:15466213 | pubmed:volume | 64 | lld:pubmed |
| pubmed-article:15466213 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15466213 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15466213 | pubmed:pagination | 7150-5 | lld:pubmed |
| pubmed-article:15466213 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:meshHeading | pubmed-meshheading:15466213... | lld:pubmed |
| pubmed-article:15466213 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15466213 | pubmed:articleTitle | Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. | lld:pubmed |
| pubmed-article:15466213 | pubmed:affiliation | Department of Biological and Technological Research and Cancer Immunotherapy and Gene Therapy Program, San Raffaele H Scientific Institute, Milan, Italy. | lld:pubmed |
| pubmed-article:15466213 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15466213 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15466213 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15466213 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15466213 | lld:pubmed |
